Published in J Pharmacol Exp Ther on December 01, 1991
Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation. Environ Health Perspect (1997) 1.08
A role for capsaicin sensitive, tachykinin containing nerves in chronic coughing and sneezing but not in asthma: a hypothesis. Thorax (1993) 0.95
Effects of topical capsaicin in seasonal allergic rhinitis. Thorax (1995) 0.83
Nonallergic rhinitis. Pathophysiology and models for study. Eur Arch Otorhinolaryngol (1995) 0.82
Effects of inhaled histamine, methacholine and capsaicin on sputum levels of alpha 2-macroglobulin. Thorax (1997) 0.81
Effects of nicotine on the human nasal mucosa. Thorax (1993) 0.80
Capsaicin-induced vasodilatation in human nasal vasculature is mediated by modulation of cyclooxygenase-2 activity and abrogated by sulprostone. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.78
Tonic stimulation of the pharyngeal mucosa causes pain and a reversible increase of inflammatory mediators. Inflamm Res (2013) 0.75
Occupational rhinitis induced by capsaicin. Allergy Asthma Immunol Res (2011) 0.75
Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc Natl Acad Sci U S A (1991) 2.41
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest (1995) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest (1987) 1.80
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA (2000) 1.62
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45
Kinins are generated during experimental rhinovirus colds. J Infect Dis (1988) 1.44
Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis (1988) 1.43
Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy (1993) 1.41
Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. Am Rev Respir Dis (1989) 1.41
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis (1991) 1.38
Heterogeneity of human mast cells. J Immunol (1983) 1.37
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37
Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol (1995) 1.33
Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol (1987) 1.32
Recombinant IL-3 induces histamine release from human basophils. J Immunol (1989) 1.31
Identification of a chymotrypsin-like proteinase in human mast cells. J Immunol (1986) 1.29
Upper respiratory tract environmental tobacco smoke sensitivity. Am Rev Respir Dis (1991) 1.27
Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. J Virol (1998) 1.26
Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils. Int Arch Allergy Appl Immunol (1991) 1.23
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J Clin Invest (1989) 1.23
IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. J Immunol (1994) 1.23
Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. Am Rev Respir Dis (1992) 1.21
Hyperosmolar triggering of histamine release from human basophils. J Clin Invest (1981) 1.21
Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis (1988) 1.21
Characterization of vagal afferent subtypes stimulated by bradykinin in guinea pig trachea. J Pharmacol Exp Ther (1999) 1.20
Bradykinin antagonists. Annu Rev Pharmacol Toxicol (1991) 1.19
Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. J Immunol (1979) 1.17
Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol (1999) 1.14
Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells. Immunology (1992) 1.14
Qualitative characteristics of histamine release from human basophils by covalently cross-linked IgE. J Immunol (1981) 1.13
Regimens of Hymenoptera venom immunotherapy. Ann Intern Med (1980) 1.12
Epithelia cells as regulators of airway inflammation. J Allergy Clin Immunol (1998) 1.12
Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest (1985) 1.11
Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol (1987) 1.11
Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol (1982) 1.10
In vivo release of inflammatory mediators by hyperosmolar solutions. Am Rev Respir Dis (1988) 1.08
A comparison of the osmotic activation of basophils and human lung mast cells. Am Rev Respir Dis (1987) 1.07
Human lung macrophage-derived histamine-releasing activity is due to IgE-dependent factors. J Immunol (1986) 1.05
Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis (1984) 1.05
Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. J Pediatr (1983) 1.04
Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest (1995) 1.04
Role of receptor aggregation in triggering IgE-mediated reactions. Fed Proc (1982) 1.03
Isolation and characterization of human intestinal mucosal mast cells. J Immunol (1985) 1.02
Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol (1985) 1.02
Cigarette smoke modulates rhinovirus-induced airway epithelial cell chemokine production. Eur Respir J (2009) 1.02
SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther (1998) 1.01
Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol (1991) 1.01
Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. J Allergy Clin Immunol (2001) 1.00
Human lung macrophages induce histamine release from basophils and mast cells. Am Rev Respir Dis (1985) 1.00
Characterization and localization of human renal kininogen. J Biol Chem (1981) 1.00
Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. J Clin Invest (1985) 0.99
Detection and partial characterization of a human mast cell carboxypeptidase. J Immunol (1987) 0.99
Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J Immunol (1998) 0.98
Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med (1987) 0.98
Human lung macrophages enhance and inhibit lymphocyte proliferation. J Immunol (1984) 0.98
Immunophenotyping and functional analysis of purified human uterine mast cells. Blood (1992) 0.97
Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J Biol Chem (1997) 0.97
A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis (1990) 0.97
Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol (1997) 0.97
Lipoxygenase products modulate histamine release in human basophils. Nature (1981) 0.97
Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol (1990) 0.97
Basophil histamine release induced by a substance from stimulated human platelets. J Immunol (1986) 0.97
Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis (1990) 0.96
Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol (1981) 0.96
Role of NF-kappa B in cytokine production induced from human airway epithelial cells by rhinovirus infection. J Immunol (2000) 0.96
Effects of tumor necrosis factor-alpha, epidermal growth factor and transforming growth factor-alpha on interleukin-8 production by, and human rhinovirus replication in, bronchial epithelial cells. Int Immunopharmacol (2001) 0.95
Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol (1989) 0.95
Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol (1996) 0.95
Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest (1987) 0.95
Prolonged maintenance interval in hymenoptera venom immunotherapy. J Allergy Clin Immunol (1981) 0.95
Studies on the allergic and nonallergic nasal inflammation. J Allergy Clin Immunol (1988) 0.95